MC4R and obesity disorder: We show that combination therapy of the MC4R agonist RM-493, which has shown to be highly selective and safe in terms of its cardiovascular profile, with the GLP-1R agonist liraglutide potently reverses diet-induced obesity and improves glucose metabolism.